NK-ocking out cancer
How newly public NantKwest fits in Soon-Shiong's empire
Patrick Soon-Shiong is building what he hopes will be a suite of companies under the NantWorks LLC umbrella that together will help revolutionize cancer treatment. The latest is cancer immunotherapy company NantKwest Inc. (NASDAQ:NK), which went public last week a little over half a year after Soon-Shiong initially invested.
NantKwest is developing cancer immunotherapies based on what it calls activated natural killer (aNK) cells,
